Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Product › Details

Kv1.3 inhibitor

	Next higher product group	immuno modulatory compound (IMO)
	Status	2017-07-18 development pp existent
	Organisation	Maruho Co., Ltd.
	Group	Maruho (Group)
	Organisation 2	4SC AG (FSE: VSC)
	Group	4SC (Group)

Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for immuno modulatory compound (IMO)

[1] Immunic, Inc.. (1/5/24). "Press Release: Immunic, Inc. Announces Private Placement of up to $240 Million". New York, NY....
[2] Odyssey Therapeutics, Inc.. (12/5/23). "Press Release: Odyssey Therapeutics Announces $101 Million Series C Financing". Boston, MA....
[3] Immunic, Inc.. (11/2/23). "Press Release: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts". New York, NY....
[4] AiCuris Anti-infective Cures AG. (7/6/23). "Press Release: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients". Wuppertal....
[5] BioNTech SE. (11/30/22). "Press Release: BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates". Mainz & Krakow....
[6] Ventus Therapeutics, Inc.. (9/29/22). "Press Release: Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program". Waltham, MA & Montréal, QC....
[7] Kupando GmbH. (9/26/22). "Press Release: Kupando Raises €13 Million in Series A Funding Round". Schönefeld....
[8] Tridek-One SAS. (9/15/22). "Press Release: Tridek-One Closes a €16 Million Financing Round to Develop First-in-Class Immune Checkpoint Agonists". Paris....
[9] Immunic, Inc.. (7/6/22). "Press Release: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén". New York, NY....
[10] Immunic, Inc.. (6/2/22). "Press Release: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]